A Multi Centre Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer (REaCT-G2)
Phase of Trial: Phase IV
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Filgrastim (Primary)
- Indications Febrile neutropenia
- Focus Adverse reactions; Therapeutic Use
- Acronyms REaCT-G2
- 28 Feb 2018 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 28 Feb 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 27 Sep 2016 Status changed from not yet recruiting to recruiting.